Szymaniak Brittany M, Morgans Alicia K, Shore Neal D
Feinberg School of Medicine at Northwestern University, Chicago, IL, USA.
Dana-Farber Cancer Institute, Boston, MA, USA.
Target Oncol. 2025 Jun 29. doi: 10.1007/s11523-025-01159-z.
Homologous recombination repair (HRR) gene alterations in prostate cancer predispose patients to more aggressive disease and a poorer prognosis. The presence of these HRR gene alterations may inform patient eligibility for clinical trials and targeted therapies, and importantly, through cascade testing, help identify family members at risk of developing an inherited cancer. This finding highlights the importance of testing for HRR gene alterations in patients with prostate cancer. Despite the potential implications of such testing to patient care, in a cross-sectional retrospective study in the USA, only 37.7% of patients with advanced prostate cancer underwent HRR testing between 2014 and 2022. The aim of this podcast is to identify obstacles to testing for HRR gene alterations that healthcare professionals encounter in day-to-day clinical practice, as well as discuss ways to potentially overcome them. In this multidisciplinary podcast, a genetic counselor, a medical oncologist, and a urologist discuss the importance of testing for HRR gene alterations and, using their different clinical perspectives, explore ways that healthcare professionals can integrate testing results into clinical practice.
前列腺癌中的同源重组修复（HRR）基因改变会使患者易患侵袭性更强的疾病且预后更差。这些HRR基因改变的存在可能会为患者是否适合参加临床试验和接受靶向治疗提供依据，重要的是，通过级联检测，有助于识别有患遗传性癌症风险的家庭成员。这一发现凸显了对前列腺癌患者进行HRR基因改变检测的重要性。尽管这种检测对患者护理有潜在影响，但在美国的一项横断面回顾性研究中，2014年至2022年间，只有37.7%的晚期前列腺癌患者接受了HRR检测。本播客的目的是找出医疗保健专业人员在日常临床实践中遇到的HRR基因改变检测障碍，并讨论可能克服这些障碍的方法。在这个多学科播客中，一位遗传咨询师、一位医学肿瘤学家和一位泌尿科医生讨论了HRR基因改变检测的重要性，并从他们不同的临床角度探讨了医疗保健专业人员将检测结果纳入临床实践的方法。
